Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.
Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, Antolini L, Mologni L, Donadoni C, Papaemmanuil E, Schnittger S, Kim DW, Boultwood J, Rossi F, Gaipa G, De Martini GP, di Celle PF, Jang HG, Fantin V, Bignell GR, Magistroni V, Haferlach T, Pogliani EM, Campbell PJ, Chase AJ, Tapper WJ, Cross NC, Gambacorti-Passerini C. Piazza R, et al. Among authors: antolini l. Nat Genet. 2013 Jan;45(1):18-24. doi: 10.1038/ng.2495. Epub 2012 Dec 9. Nat Genet. 2013. PMID: 23222956 Free PMC article.
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.
Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E, D'Emilio A, Stagno F, le Coutre P, Hurtado-Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, Assouline S, Durosinmi MA, Leeksma O, Pogliani EM, Puttini M, Jang E, Reiffers J, Piazza R, Valsecchi MG, Kim DW. Gambacorti-Passerini C, et al. Among authors: antolini l. J Natl Cancer Inst. 2011 Apr 6;103(7):553-61. doi: 10.1093/jnci/djr060. Epub 2011 Mar 21. J Natl Cancer Inst. 2011. PMID: 21422402 Clinical Trial.
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients.
Gambacorti Passerini C, Farina F, Stasia A, Redaelli S, Ceccon M, Mologni L, Messa C, Guerra L, Giudici G, Sala E, Mussolin L, Deeren D, King MH, Steurer M, Ordemann R, Cohen AM, Grube M, Bernard L, Chiriano G, Antolini L, Piazza R. Gambacorti Passerini C, et al. Among authors: antolini l. J Natl Cancer Inst. 2014 Feb;106(2):djt378. doi: 10.1093/jnci/djt378. J Natl Cancer Inst. 2014. PMID: 24491302 Clinical Trial.
Acute myeloid leukaemia niche regulates response to L-asparaginase.
Michelozzi IM, Granata V, De Ponti G, Alberti G, Tomasoni C, Antolini L, Gambacorti-Passerini C, Gentner B, Dazzi F, Biondi A, Coliva T, Rizzari C, Pievani A, Serafini M. Michelozzi IM, et al. Among authors: antolini l. Br J Haematol. 2019 Aug;186(3):420-430. doi: 10.1111/bjh.15920. Epub 2019 May 1. Br J Haematol. 2019. PMID: 31044436 Free article.
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation.
Diral E, Mori S, Antolini L, Abruzzese E, Le Coutre P, Martino B, Pungolino E, Elena C, Bergamaschi M, Assouline S, Di Bona E, Gozzini A, Andrade-Campos M, Stagno F, Iurlo A, Pirola A, Fontana D, Petiti J, Bonanomi ML, Crivori P, Piazza R, Fava C, Gambacorti-Passerini C. Diral E, et al. Among authors: antolini l. Blood. 2020 Nov 5;136(19):2237-2240. doi: 10.1182/blood.2019004371. Blood. 2020. PMID: 32518953 Free article. No abstract available.
Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study.
Gemelli M, Elli EM, Elena C, Iurlo A, Intermesoli T, Maffioli M, Pungolino E, Carraro MC, D'Adda M, Lunghi F, Anghileri M, Polverelli N, Rossi M, Bacciocchi M, Bono E, Bucelli C, Passamonti F, Antolini L, Gambacorti-Passerini C. Gemelli M, et al. Among authors: antolini l. Blood Res. 2020 Sep 30;55(3):139-145. doi: 10.5045/br.2020.2020130. Blood Res. 2020. PMID: 32792470 Free PMC article.
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia.
Gambacorti-Passerini C, Nicolini FE, Larson RA, Aroldi A, Fontana D, Piazza R, le Coutre P, Antolini L, Assouline S. Gambacorti-Passerini C, et al. Among authors: antolini l. Am J Hematol. 2022 Aug;97(8):E296-E298. doi: 10.1002/ajh.26618. Epub 2022 Jun 9. Am J Hematol. 2022. PMID: 35604243 Free PMC article. No abstract available.
134 results